Hepatitis C screening, what the guidelines actually say

Hepatitis C screening is a guideline that got dramatically simpler in 2020, not because the evidence changed direction but because the Task Force decided the old way of narrowing the target population was leaving too many infections undetected.

What this screening is and what it looks for

Hepatitis C virus (HCV) is a blood-borne infection that can cause chronic liver disease, cirrhosis, and liver cancer, often with no symptoms for years or decades. Screening uses a blood test for HCV antibodies; a positive antibody result is followed by a confirmatory test for the virus’s RNA to determine whether the infection is current, since some people clear an HCV infection on their own and would have a positive antibody test without an active infection. The USPSTF describes HCV as the most commonly reported blood-borne infection in the United States, and notes that direct-acting antiviral treatments now cure the large majority of people who are treated.

Who and when, per the USPSTF

The 2020 recommendation sets one population and one grade, a deliberately broad standard compared to what came before:

• Adults aged 18 to 79: Grade B. The Task Force recommends screening for HCV infection in this entire age range, concluding with moderate certainty that it has a substantial net benefit, without narrowing eligibility by risk factor, birth year, or symptoms.
• Testing frequency. The Task Force describes one-time screening as appropriate for most adults in this age range. For people with an ongoing risk factor for HCV, injection drug use is the example the Task Force gives, it describes periodic rescreening as appropriate rather than a single lifetime test.

This age-based, not risk-based, eligibility is itself the headline of the 2020 update. These bands describe who the guideline recommends screening and on what schedule, not an instruction that any particular person should be tested on a particular date. Whether you fall inside or outside the 18-to-79 window, and how any risk factor you have should shape your testing frequency, is a conversation for a clinician who knows your history.

The evidence and its grade

Before 2020, the USPSTF’s standing recommendation, set in 2013, targeted people at high risk for HCV infection and added a one-time screen for adults born between 1945 and 1965, the birth cohort found to carry a disproportionate share of undiagnosed infections, largely tied to the era’s blood transfusion and injection practices before modern screening and safety measures. That birth-cohort approach caught a real, concentrated pocket of cases, but it missed people outside it, including younger adults, a group where HCV cases tied to the opioid epidemic and injection drug use had been rising. The Task Force’s 2020 statement concludes with moderate certainty that expanding to all adults 18 to 79 has a substantial net benefit, weighing the low harm of a blood test against modeling evidence that broader screening would identify a large number of additional infections in a group the birth-cohort rule did not reach. The upper age bound at 79, rather than open-ended, tracks the population the Task Force’s evidence review actually covered; it is not a statement that HCV risk disappears at 80.

Where the guidance differs

The CDC’s own 2020 recommendations for hepatitis C screening among adults align closely with the USPSTF’s age-based approach, both bodies moved to universal screening for the same 18-to-79 population around the same time, so this is not a case of competing numbers. The more consequential difference sits outside the general adult recommendation entirely: the American College of Obstetricians and Gynecologists recommends HCV screening for all pregnant people during each pregnancy, without an age ceiling, a position aimed at a different clinical moment (pregnancy) than the USPSTF’s general population statement, and one that does not stop applying at 79 the way the general adult recommendation does on paper. These are two guidelines answering two different questions, general adult screening versus prenatal screening, not a disagreement about the same population.

Questions to ask your clinician

Framed as questions to bring to a visit, not as steps to take on your own:

• Am I in the 18-to-79 age range this recommendation covers, and have I actually been screened for HCV, or is this something I should ask about?
• I have an ongoing risk factor, such as injection drug use; how often should I be rescreened rather than relying on a single lifetime test?
• If a screening antibody test comes back positive, what is the confirmatory step, and what does it tell me about whether I have a current infection?
• I am pregnant or planning to become pregnant; how does the ACOG recommendation for screening during pregnancy apply to me alongside or instead of the general adult guideline?
• I am outside the 18-to-79 window; does that mean the guideline has nothing to say about my situation, or should something else factor into whether I get tested?

You can compare this profile against the full Guideline Tracker, read the sibling profile for depression screening, or see how everyday choices fit alongside screening in the big levers.